NCT02587325View on ClinicalTrials.gov

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

August 16, 2022

Study Completion Date

September 16, 2022

Conditions
Pulmonary Hypertension
Interventions
DRUG

nab-sirolimus

nab-sirolimus is an mTOR inhibitor

Trial Locations (6)

15213

University of Pittsburgh Medical Center, Pittsburgh

20892

National Institutes of Health, Bethesda

22042

Inova Fairfax Hospital, Falls Church

46202

Indiana University, Indianapolis

85724

University of Arizona, Tucson

90502

Harbor-UCLA Medical Center, Torrance

Sponsors
All Listed Sponsors
lead

Aadi Bioscience, Inc.

INDUSTRY